• EN

Drug-related infectious diseases (DRID)

Prevalence of HIV, HCV and HBV in IDUs

Tables INF-1, INF-2 and INF-3 provide a summary overview of latest available data on HIV, HCV and HBV prevalence in samples of injecting drug users.

Tables INF-108, INF-109 and INF-110 show full data on HIV prevalence in samples of injecting drug users, as well as prevalence among young injectors and new injectors for HIV (see also Figure INF-3).

Tables INF-111, INF-112 and INF-113 show full data on HCV prevalence in samples of injecting drug users as well as prevalence among young injectors and new injectors for HCV (see also Figure INF-6).

Table INF-114 and Table INF-115 show full data on prevalence of HBV current infection (HBsAg) and of HBV antibodies (aHBc, aHBs), respectively (see also Figure INF-9).

Table INF-117 shows prevalence of HIV, HCV and HBV markers among (injecting) drug users in prison. Part (i) shows prevalence of HIV infection, part (ii) of hepatitis C antibodies, part (iii) of HBsAg, a marker of current hepatitis B infection, and part (iv) of hepatitis B antibodies.

HIV case reporting and hepatitis B/C notifications

Tables INF-104 show HIV case reporting data. These data, provided by ECDC–WHO/Europe, are both provided as case counts and as rates per million population (see also Figure INF-1 and Figure INF-2).

Tables INF-105 and INF-106 show notifications of newly diagnosed HCV and HBV cases, respectively. For hepatitis notifications, rates per million are not calculated, given the likely low comparability of the data between countries. These tables also give the percentage of IDUs among the cases of hepatitis C and B that have information on the presumed transmission category.

Table INF-107: a small number of countries report incidence data for HCV from follow-up studies of IDUs at mostly sub-national level. Table INF-107 reports the number of IDUs followed, the number of sero-conversions, follow-up time, the incidence rate per 100 person-years.

Table INF-0 lists all bibliographic references.

The table below summarises the overall organisation of the core set of tables and graphs.



Hepatitis C

Hepatitis B

Prevalence — latest data overview

Table INF-1 and Figure INF-3

Table INF-2 and Figure INF-6

Table INF-3 and Figure INF-9

Prevalence — full data and time trends

Table INF-108

Table INF-111

Table INF-115, Table INF-115

Prevalence — full data and time trends in young and new IDUs

Table INF-109, Table INF-110

Table INF-112, Table INF-113


Case reports/notifications

Table INF-104, Figure INF-1 and Figure INF-2

Table INF-105

Table INF-106


About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Monday, 16 November 2009